Related Experiment Video
Updated: Mar 13, 2026
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
The Impact of Tobacco Smoking on Treatment Response Among Patients With Psoriasis Undergoing Biologic Treatment:
Fanlingzi Shen1, Yuning Ding1, Xiuqi Zhang2
1Clinical Research Center, Shanghai Skin Disease Hospital, 1278 Baode Road, Shanghai, Shanghai, 200443, China, 86 13816845803.
Background:
Tobacco smoking is viewed as a behavioral risk factor for psoriasis initiation and progress, even among those undergoing biologic treatment. However, evidence regarding the association between tobacco smoking and treatment response to biologics among patients with psoriasis is limited.
Objective:
This study aimed to explore the impact of tobacco smoking on the efficacy of biologic treatment in patients with psoriasis.
Methods:
Patients with psoriasis undergoing biologic treatment were recruited from 2022 to 2024 at the Shanghai Skin Disease Hospital. Demographic characteristics and smoking habits were collected using a structured questionnaire. Clinical features and treatment efficacy were assessed and recorded by dermatologists at baseline and weeks 4, 8, 12, 24, and 48 after treatment, and the Psoriasis Area and Severity Index (PASI) 75 and PASI 90 measures were calculated for treatment efficacy evaluation.
Results:
A total of 192 patients with psoriasis were included, of whom 78 (40.6%) were tobacco smokers, with a higher smoking prevalence observed in male patients (74/154, 48.1%). The PASI 75 response rates at weeks 4, 8, 12, 24, and 48 were 29.2% (56/192), 54.2% (104/192), 78.6% (151/192), 84.5% (153/181), and 82.7% (134/162), respectively. The PASI 90 response rates increased from 13.0% (25/192) at week 4 to 62.4% (113/181) at week 24 and 59.9% (97/162) at week 48. Logistic regression analysis indicated that nonsmoking patients with psoriasis had a high PASI 75 response rate. The adjusted odds ratios were 2.57 (95% CI 1.19-5.53), 2.61 (95% CI 1.34-5.08), 2.62 (95% CI 1.13-6.04), 2.27 (95% CI 0.89-5.75), and 2.75 (95% CI 1.01-7.49) at weeks 4, 8, 12, 24, and 48, respectively. Moreover, nonsmoking patients with psoriasis also had a higher PASI 90 response rate than those who smoked. The odds ratios ranged from 1.32 (95% CI 0.49-3.54) to 2.59 (95% CI 1.21-5.55). Correlation analysis showed that both tobacco smoking duration and daily cigarette consumption were negatively correlated with the reduction in PASI score at weeks 4 to 48 after treatment (P<.05).
Conclusions:
Tobacco smoking was negatively associated with treatment response among patients with psoriasis undergoing biologic treatment, especially among patients with longer tobacco smoking duration and higher daily cigarette consumption.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...